- Home
- HESM vs RNA Comparison
HESM vs RNA Comparison
Compare HESM & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HESM
- RNA
- Stock Information
- Founded
- HESM 2014
- RNA 2012
- Country
- HESM United States
- RNA United States
- Employees
- HESM N/A
- RNA N/A
- Industry
- HESM Oil & Gas Production
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- HESM Energy
- RNA Health Care
- Exchange
- HESM Nasdaq
- RNA Nasdaq
- Market Cap
- HESM 4.3B
- RNA 4.0B
- IPO Year
- HESM N/A
- RNA 2020
- Fundamental
- Price
- HESM $33.66
- RNA $69.66
- Analyst Decision
- HESM Hold
- RNA Buy
- Analyst Count
- HESM 9
- RNA 20
- Target Price
- HESM $41.44
- RNA $69.26
- AVG Volume (30 Days)
- HESM 1.5M
- RNA 7.5M
- Earning Date
- HESM 11-03-2025
- RNA 11-07-2025
- Dividend Yield
- HESM 8.73%
- RNA N/A
- EPS Growth
- HESM 17.37
- RNA N/A
- EPS
- HESM 2.69
- RNA N/A
- Revenue
- HESM $1,570,600,000.00
- RNA $10,729,000.00
- Revenue This Year
- HESM $13.07
- RNA N/A
- Revenue Next Year
- HESM $5.85
- RNA $108.26
- P/E Ratio
- HESM $12.56
- RNA N/A
- Revenue Growth
- HESM 9.02
- RNA 1.23
- 52 Week Low
- HESM $31.63
- RNA $21.51
- 52 Week High
- HESM $44.14
- RNA $70.51
- Technical
- Relative Strength Index (RSI)
- HESM 41.61
- RNA 79.48
- Support Level
- HESM $33.50
- RNA $69.65
- Resistance Level
- HESM $34.24
- RNA $72.05
- Average True Range (ATR)
- HESM 0.56
- RNA 1.98
- MACD
- HESM 0.33
- RNA 2.39
- Stochastic Oscillator
- HESM 77.59
- RNA 90.77
About HESM Hess Midstream LP Share
Hess Midstream LP owns, operates, develops, and acquires a diverse set of midstream assets and provides fee-based services to Hess and third-party customers. It conducts its business through three operating segments: gathering, processing and storage, and terminaling and exporting. The company derives the maximum revenue from the gathering segment. Its gathering segment consists of the following assets namely Natural Gas Gathering and Compression; Crude Oil Gathering and Produced Water Gathering and Disposal.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.